Open original FDA record ↗Recall record
- FDA identifier
- Z-1425-2012
- Company in FDA record
- Abbott Laboratories Inc.
- FDA classification date
- Apr 16, 2012
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 17, 2026
- Recall classification
- Unknown — no matched enforcement classification
Reason stated in the source
Abbott Laboratories has issued a recall on the Clinical Chemistry Total Bilirubin due to an under-recovery on one clinical neonatal specimen resulting in a value less than the assay linear limit.
Source facts
- Action
- Abbott Laboratories plans to release a Product Correction letter to customers instructing customers to follow the steps provided in order to revise their Total Bilirubin assay parameters. The letter explained the reason for the recall, along with the patient impact. Customers were to keep the letter as part of their laboratory records and also forward a copy to any other laboratories that they may have forwarded Total Bilirubin kits. U.S. Customers should contact Customer Service at 1-877-4ABBOTT, if they have questions.
- Initiated
- 2009-07-09
- Root cause
- Material/Component Contamination
- Terminated
- 2014-03-07
- Distribution
- Worldwide Distribution -- USA, Guatemala, Chile, Brazil, Canada, Germany, Hong Kong, Thailand, Puerto Rico, Australia, New Zealand, Trinidad & Tobago, Bermuda, Curacao, Cayman Island, and Jamaica.
- Recall number
- Z-1425-2012
- Recall status
- Terminated
- CDRH record ID
- 83856
- FDA classified
- 2012-04-16
- Recall event number
- 52748